­
­
­
­

Inventi Impact: Med Chem

Articles

  • Inventi:pmc/46517/22
    Synthesis of Novel N4-Hydrocytidine Analogs as Potential Anti-SARS-CoV-2 Agents
    01-Jan-2023 Research 2023 : January-March
    Franck Amblard, Julia C LeCher, Ramyani De, Shu Ling Goh, Chengwei Li, Mahesh Kasthuri, Nicolas Biteau, Longhu Zhou, Zahira Tber, Jessica Downs-Bowen, Keivan Zandi, Raymond F Schinazi

    Coronavirus disease 2019 (COVID-19) is an emerging global pandemic with severe morbidity and mortality caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Molnupiravir, an ester prodrug form of N4-hydroxycytidine (NHC), was recently emergency-use approved for the treatment of early SARS-CoV-2 infections. Herein, we report the synthesis and evaluation of a series of novel NHC analogs.

    How to Cite this Article
    Attribution/ CC Compliant Citation: Amblard, Franck, et al. "Synthesis of Novel N 4-Hydrocytidine Analogs as Potential Anti-SARS-CoV-2 Agents." Pharmaceuticals 15.9 (2022): 1144. https://doi.org/10.3390/ph15091144 http://creativecommons.org/licenses/by/4.0/ Some formatting elements, header, footer, logos, dates and pagination were modified while adapting this article.
    Download Full Text